Asterias Biotherapeutics, Inc.
(UNKNOWN : AST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
-0.15%46.308.1%$691.09m
AMGNAmgen Inc.
0.54%178.421.3%$499.78m
CELGCelgene Corporation
-0.29%91.271.3%$433.17m
GILDGilead Sciences, Inc.
0.42%67.220.9%$403.69m
BIIBBiogen Inc.
-0.61%230.141.3%$373.22m
ILMNIllumina, Inc.
0.59%304.073.5%$356.24m
REGNRegeneron Pharmaceuticals, Inc.
0.31%299.292.6%$268.19m
SRPTSarepta Therapeutics, Inc.
0.97%154.7414.7%$198.20m
ALXNAlexion Pharmaceuticals, Inc.
0.39%123.302.0%$197.77m
VRTXVertex Pharmaceuticals Incorporated
0.63%177.271.9%$181.85m
AAgilent Technologies, Inc.
0.07%70.001.6%$140.92m
EXASExact Sciences Corporation
0.64%115.6824.1%$137.17m
INCYIncyte Corporation
-0.41%79.552.5%$109.41m
BLUEBluebird Bio, Inc.
1.88%136.1714.3%$95.57m
BMRNBioMarin Pharmaceutical Inc.
-0.98%81.564.3%$83.49m

Company Profile

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.